Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News

robot
Abstract generation in progress

Oppenheimer has upgraded Vertex Pharmaceuticals (VRTX) to an “Outperform” rating with a price target of $540.00 USD. This upgrade follows several other positive analyst revisions for VRTX in early 2026. Vertex Pharmaceuticals is a biotechnology company known for its cystic fibrosis drugs, and it is expanding its portfolio into gene-editing therapies and non-opioid pain medication.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)